Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2001-01-04
2003-05-20
Nguyen, Dave T. (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C435S091400, C435S455000
Reexamination Certificate
active
06566342
ABSTRACT:
FIELD OF THE INVENTION
This invention relates generally to the field of gene therapy and more particularly to the application of gene therapy to the cells of a secretory gland.
BACKGROUND OF THE INVENTION
Although gene therapy and specifically human gene therapy has been widely discussed only over the last five years, the basic idea first became a reality in 1944 when Avery et al. carried out research on the chemical nature of substances inducing transformation of pneumococcal types. (Avery et al.,
J. Exp. Med.
79:137-158, 1944). The work carried out by Avery et al., did not involve the actual insertion of genetic material into cells in order to carry out gene therapy. The insertion of new genetic material into cells in order to permanently affect the genetic makeup of the cells is the methodology now generally referred to as gene therapy.
Current gene therapy is carried out in a variety of ways but involves two general protocols. In the first method, referred to as ex vivo gene therapy, cells are extracted from an organism such as a human and subsequently subjected to genetic manipulation by a variety of different means. After genetic material has been properly inserted into the cells, the cells are implanted back into the body from which they were removed. Thus the process involves cell removal, transformation of the cells in vitro, and subsequent reintroduction of the modified cells into the patient. Persistent, in vivo expression of the newly implanted genetic material after transplantation of the transformed cells has been successful (see Morgan et al.,
Science
237:1476 (1987); and Gerrard et al.,
Nat. Genet.
3:180 (1993)).
In the second approach to gene therapy, referred to as in vivo gene therapy, somatic cells within a living organism are transformed with new genetic material. For example, the genetic material to be introduced into the organism is packaged within a retrovirus or adenovirus. The virus containing the desired genetic material is allowed to infect target cells within the organism. Upon infection of the cells, the virus injects genetic material into the cells which is then integrated into the cells' genome. As a result, the injected genetic material is expressed and the patient is treated.
Several different methods for transforming cells can be used in accordance with either the ex vivo or in vivo transfection procedures. For example, various mechanical methods can be used to deliver the genetic material, including the use of fusogenic lipid vesicles (liposomes incorporating cationic lipids such as lipofection; see Felgner et al.,
Proc. Natl. Acad. Sci. U.S.A.
84:7413-7417 (1987)); direct injection of DNA (Wolff, et al.,
Science
(1990) 247:1465-1468); and pneumatic delivery of DNA-coated gold particles with a device referred to as the gene gun (Yang et al.,
Proc. Natl. Acad. Sci. U.S.A.
1990; 87:1568-9572).
Ex vivo and in vivo gene transfer methodologies have been accomplished using a variety of different procedures, such as the use of retroviruses or direct injection. The procedures have been used on five general types of cells in order to carry out (1) liver cell gene therapy; (2) hematopoietic cell gene therapy; (3) cancer cell gene therapy; (4) respiratory cell gene therapy; and (5) muscle cell gene therapy. A review of the different techniques along with a citation of numerous publications in each area is contained within a recent article on human gene therapy (see Morsy et al.,
JAMA
270:2338-2345 (1993)).
Depending on the desired result, the effect which the inserted genetic material will have on the transformed cell can vary greatly and can be selected according to the specific therapeutic situation. For example, genetic material inserted into the cells in order to obtain circulation of the expressed genetic products would not be used in connection with the treatment of cancer cells of a localized tumor. Stated differently, gene therapy may be carried out in order to locally affect a given type of cells such as affecting cancer cells within a tumor or locally affecting liver cells. Other types of gene therapy are carried out in order to cause the manipulated cells to express a protein which is transported to the circulatory system and systemically delivered to the organism. Genetic manipulation of cells to express a protein for systemic delivery to the organism has been problematic. The present invention addresses this problem.
SUMMARY OF THE INVENTION
Secretory gland cells are genetically altered to operatively incorporate a gene which expresses a therapeutically effective protein. More particularly, cells of a salivary gland or the pancreas are genetically altered to operatively incorporate DNA which when expressed produces a protein which has a desired therapeutic effect on the patient. The expressed protein is secreted directly into the blood stream and/or into the gastrointestinal system to obtain therapeutic levels of the protein, thereby treating the patient in need of the protein.
A primary object is to provide a method of gene therapy wherein cells of a secretory gland, preferably the pancreas or a salivary gland, more preferably a parotid gland, of a mammal are genetically modified to express a biologically active and therapeutically useful protein which protein is secreted into the circulatory system and/or the gastrointestinal tract of the individual.
Another object is to produce genetically transformed secretory gland cells which cells have incorporated into their genome genetic material which expresses a biologically active and therapeutically useful protein and secretes that protein into the surrounding media.
An advantage of the present invention is that long term therapeutic cures can be provided for diseases wherein individuals are suffering from the disease due to a deficiency in a particular protein. A feature of the present invention is that cells of a secretory gland, preferably the pancreas or a salivary gland, more preferably a parotid gland, are specifically targeted.
Another advantage of the present invention is that the expressed protein is secreted into the circulatory system and saliva or pancreatic juices of the patient to provide a systemic effect.
These and other objects, advantages and features of the present invention will become apparent to those persons skilled in the art upon reading the details of the vectors, cell lines and methodology as more fully set forth below.
REFERENCES:
patent: 4394443 (1983-07-01), Weissman et al.
patent: 4683195 (1987-07-01), Mollis et al.
patent: 4683202 (1987-07-01), Mollis
patent: 4703008 (1987-10-01), Lin
patent: 4861719 (1989-08-01), Miller et al.
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5166320 (1992-11-01), Wu et al.
patent: 5219740 (1993-06-01), Miller et al.
patent: 5240846 (1993-08-01), Collins et al.
patent: 5292662 (1994-03-01), Sandmeyer
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5356806 (1994-10-01), Harris et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5766899 (1998-06-01), Kuo et al.
patent: 6265387 (2001-07-01), Wolff et al.
patent: WO 91/06309 (1991-05-01), None
patent: WO 93/19660 (1993-10-01), None
patent: WO 94/26915 (1994-11-01), None
patent: WO 94/29471 (1994-12-01), None
Genes in a bottle pp. 132-136 vol. 10 1992.*
Hickman et al. Gene expression following direct injection of DNA into liver pp. 1477-1483 1994.*
Bruinsma et al. Gene therapy meeting cold spring harbor, p. 102-103 1994.*
Gerrard et al. T. cell biochem, suppl. 18A, 241, 1994, DZ403 p. 241.*
Tripathy, S.K. et al. “Stable delivery of physiologic levels of recombinant erythropoietin to the systemic circulation by intramuscular injection of replication-defective edenovirus”Proc. Natl. Acad. Sci.USA, Nov. 1994, pp. 11557-11561, vol. 91.
Hatzoglou, M. et al. “Hepatic Gene Transfer in Animals Using Retroviruses Containing the Promoter from the Gene for Phosphoenolpyruvate Carboxykinase”The Journal of Biological Chemistry, Oct. 1990, pp. 17285-17293, vol. 265.
Valera et al. “Regulated Expression of Human Ins
German Michael
Goldfine Ira D.
Rothman Stephen S.
Borden Paula A.
Bozicevic Field & Francis LLP
Francis Carol L.
Nguyen Dave T.
The Regents of the University of California
LandOfFree
Gene therapy by secretory gland expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gene therapy by secretory gland expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene therapy by secretory gland expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3033635